Navigation Links
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Date:2/6/2012

NEW YORK, Feb. 6, 2012  /PRNewswire/ --  Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0769058/Commercializing-Angiogenesis-Affecting-Drugs-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have angiogenesis affecting properties.This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).

This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report: * The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.

* Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.

* Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.

* Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..

* The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.

* The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.1 Executive Summary 32 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'™ Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 224.2 List of Tables225 Introduction 375.1 The Scope of this Report 375.2 Definitions 405.3 Abbreviations 406 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 416.1 Drug Repositioning in Oncology 416.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology 426.2.1 Calcium Ion Binding Targets 486.2.2 Carboxy-lyase Activity Targets 496.2.3 Catalytic Activity Targets 516.2.4 Cell Adhesion Molecule Activity Targets 566.2.5 Chaperone Activity Targets 636.2.6 Chemokine Activity Targets 676.2.7 Cofactor Binding Targets 696.2.8 Cysteine-type Peptidase Activity Targets 716.2.9 Cytokine Activity Targets 766.2.10 Cytoskeletal Protein Binding Targets 806.2.11 DNA Topoisomerase Activity Targets 816.2.12 DNA-directed DNA Polymerase Activity Targets 846.2.13 Extracellular Matrix Structural Constituent Targets 856.2.14 G-protein Coupled Receptor Activity Targets 916.2.15 Growth Factor Activity Targets 966.2.16 GTPase Activity Targets 1126.2.17 Hormone Activity Targets 1156.2.18 Hydrolase Activity Targets 1166.2.19 Kinase Activity Targets 1186.2.20 Kinase Binding Targets 1216.2.21 Lipid Kinase Activity Targets 1236.2.22 Metallopeptidase Activity Targets 1306.2.23 Molecular Function Unknown Targets 1486.2.24 Motor Activity Targets 1496.2.25 Oxidoreductase Activity Targets 1516.2.26 Peptidase Activity Targets 1536.2.27 Phosphoric Diester Hydrolase Activity Targets 1696.2.28 Protease Inhibitor Activity Targets 1726.2.29 Protein Binding Targets 1766.2.30 Protein Serine/Threonine Kinase Activity Targets 1806.2.31 Protein-tyrosine Kinase Activity Targets 2096.2.32 Receptor Activity Targets 2206.2.33 Receptor Binding Targets 2456.2.34 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 2516.2.35 RNA Binding Targets 2536.2.36 Serine-type Peptidase Activity Targets 2546.2.37 Structural Constituent of Cytoskeleton Targets 2596.2.38 Superoxide Dismutase Activity Targets 2616.2.39 Transcription Factor Activity Targets 2646.2.40 Transcription Regulator Activity Targets 2776.2.41 Transferase Activity Targets 2846.2.42 Translation Regulator Activity Targets 2866.2.43 Transmembrane Receptor Activity Targets 2936.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 2956.2.45 Transporter Activity Targets 3486.2.46 Ubiquitin-specific Protease Activity Targets 3526.2.47 Unknown Function Targets 3536.2.48 Voltage-gated Ion Channel Activity Targets 3546.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology 3556.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3556.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets 3606.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 3646.6 The Drug-Target Competitive Landscape 3686.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology 3726.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology 3756.8.1 Tools for Analysis of Cancer Pathways 3766.8.2 Pathway Assessment 3777 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development 4247.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4267.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4287.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4317.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4387.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4467.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology 4507.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology 4547.7.1 Marketed 4587.7.2 Pre-registration 4737.7.3 Phase III 4777.7.4 Phase II 5157.7.5 Phase I 5517.7.6 Preclinical 5827.7.7 Suspended 6187.7.8 Ceased 6197.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology 6608 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy 6678.1 Small Molecules 6698.1.1 Background 6698.1.2 Target Strategies of Small Molecule Drugs 6708.2 Peptide & Protein Drugs 6828.2.1 Background 6828.2.2 Target Strategies of Peptide and Protein Drugs 6838.3 Antibodies 6898.3.1 Background 6898.3.2 Target Strategies of Antibody Drugs 6898.4 Nucleic Acid Therapies 6948.4.1 Background 6948.4.2 Target Strategies of Nucleic Acid Drugs 6958.5 Gene Therapy 6978.5.1 Background 6978.5.2 Target Strategies of Gene Therapy Drugs 6978.6 Drug Delivery and Nanotechnology 7008.6.1 Background 7008.6.2 Target Strategies of Reformulated Drugs 7008.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 7039 Selecting Indication for Angiogenesis Affecting Drugs in Oncology 7109.1 Acute Lymphocytic Leukemia 7139.2 Acute Myelogenous Leukemia 7149.3 Adrenal Cancer 7179.4 B-cell Lymphoma 7189.5 Basal Cell Cancer 7199.6 Biliary Cancer 7209.7 Bladder Cancer 7219.8 Bone Cancer 7249.9 Brain Cancer 7259.10 Breast Cancer 7289.11 Cancer (general) 7349.12 Carcinoid 7359.13 Cervical Cancer 7379.14 Chemopreventative 7389.15 Chronic Lymphocytic Leukemia 7399.16 Chronic Myelogenous Leukemia 7409.17 Chronic Myelomonocytic Leukemia 7419.18 CNS Cancer 7419.19 Colorectal Cancer 7429.20 Endometrial Cancer 7489.21 Fallopian Tube Cancer 7509.22 Fibro Sarcoma 7529.23 Gastrointestinal Cancer (general) 7539.24 Gastrointestinal Stomach Cancer 7569.25 Gastrointestinal Stromal Cancer 7599.26 Head and Neck Cancer 7619.27 Hematological Cancer (general) 7649.28 Hodgkin's Lymphoma 7659.29 Kaposi's Sarcoma 7669.30 Leiomyo Sarcoma 7679.31 Leukemia (general) 7689.32 Lipo Sarcoma 7699.33 Liver Cancer 7709.34 Lung Cancer (general) 7749.35 Lymphangioleiomyomatosis 7769.36 Lymphoma (general) 7779.37 Mast Cell Leukemia 7799.38 Mastocytosis 7799.39 Melanoma 7809.40 Mesothelioma 7849.41 Myelodysplastic Syndrome 7879.42 Myeloma 7899.43 Nasopharyngeal Cancer 7929.44 Neuroendocrine Cancer (general) 7939.45 Neuroendocrine Cancer (pancreatic) 7949.46 Neurofibromatosis 7969.47 non-Hodgkin's Lymphoma 7979.48 Non-Small Cell Lung Cancer 7999.49 Oesophageal Cancer 8059.50 Oral Cancer 8079.51 Osteo Sarcoma 8089.52 Ovarian Cancer 8099.53 Pancreatic Cancer 8139.54 Peritoneal Cancer 8169.55 Prostate Cancer 8189.56 Radio/chemotherapy-induced Alopecia 8229.57 Radio/chemotherapy-induced Infection 8229.58 Renal Cancer 8239.59 Sarcoma (general) 8289.60 Small Cell Lung Cancer 8309.61 Soft Tissue Sarcoma 8339.62 Solid Tumor 8359.63 Squamous Cell Cancer 8399.64 Synovial Sarcoma 8409.65 T-cell Lymphoma 8419.66 Testicular Cancer 8429.67 Thyroid Cancer 8439.68 Unspecified 8459.69 Vaccine adjunct 8489.70 Waldenstrom's hypergammaglobulinemia 84810 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 84910.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 85310.2 Company Facts and Ranking 85510.3 Competitive Fall-Out Assessment 86110.4 Abbott 86410.5 Acceleron Pharma 87510.6 Access 87910.7 Active Biotech 88310.8 Adherex 88710.9 Advantagene 89510.10 Advaxis 90110.11 Advenchen 90510.12 Aeterna Zentaris 90910.13 Agennix 91610.14 Aida Pharmaceuticals 92010.15 Alnylam 92410.16 Ambit Biosciences 92810.17 Ambrilia Biopharma 93410.18 Amgen 93810.19 Amphora 94610.20 Angiogen 95010.21 Angiogenex 95410.22 Angstrom Pharmaceuticals 95810.23 Ansaris 96210.24 Antisoma 96610.25 Arana Therapeutics 97010.26 Ariad 97410.27 Arno Therapeutics 98410.28 ArQule 98810.29 Array BioPharma 99410.30 Astellas 99810.31 Astex Therapeutics 100410.32 AstraZeneca 100810.33 Attenuon 101610.34 Austrianova 102210.35 Bayer 102610.36 BioAlliance Pharma 103610.37 BioAxone 104110.38 Biocad 104510.39 Boehringer Ingelheim 105110.40 Bolder BioTechnology 105710.41 Bristol-Myers Squibb 106310.42 BTG 107510.43 Cancer Research Technology 108110.44 CDG Therapeutics 108510.45 Celecure 108910.46 Celera 109310.47 Celgene 109710.48 Cell Therapeutics 110510.49 CellCeutix 111010.50 Cellmid 111410.51 Cephalon 111810.52 ChemoCentryx 112210.53 Chemokine Therapeutics 112610.54 China Sky One Medical 113010.55 Choongwae 113410.56 Circadian Technologies 113910.57 Cue Biotech 114410.58 Curis 114810.59 Cyclacel 115410.60 Cytochroma 115810.61 Deciphera Pharmaceuticals 116210.62 Dendreon 116610.63 Dyax 117010.64 Eisai 117410.65 Eli Lilly 118110.66 EntreMed 119510.67 Exelixis 120610.68 ExonHit Therapeutics 121810.69 Five Prime Therapeutics 122210.70 GammaCan 122610.71 Genmab 123310.72 Gilead Sciences 124010.73 GlaxoSmithKline 124710.74 GlycoGenesys 125410.75 Green Cross 125910.76 Hoffmann-La Roche 126410.77 Hy BioPharma 127610.78 Idera Pharmaceuticals 128010.79 ImClone Systems 128710.80 ImmunoGen 129210.81 ImmuPharma 129610.82 Introgen Therapeutics 130010.83 Isis Pharmaceuticals 130510.84 Johnson & Johnson 130910.85 KAI Pharmaceuticals 131710.86 Karus Therapeutics 132210.87 Kirin Pharma 132610.88 Kringle Pharma 133010.89 Kyowa Hakko Kirin 133410.90 Lee's Pharmaceutical 134010.91 Lorus Therapeutics 134410.92 MAT Biopharma 134810.93 MediGene 135210.94 Merck & Co 135810.95 Merck KGaA 136210.96 Mersana Therapeutics 136910.97 MethylGene 137310.98 Micromet 137710.99 MolMed 138110.100 Morvus Technology 138610.101 NewSouth Innovations 139010.102 Non-industrial Source 139410.103 Novartis 139810.104 Novelix 141710.105 Noxxon 142110.106 Oasmia 142510.107 Onconova 142910.108 OncoTherapy Science 143510.109 Oncothyreon 144110.110 OSI Pharmaceuticals 144610.111 Oxford BioMedica 145110.112 OXiGENE 145510.113 Pepscan Therapeutics 146110.114 PepTx 146810.115 Peregrine Pharmaceuticals 147210.116 Pfizer 147910.117 Pharmacopeia 149910.118 PharmaMar 150410.119 Pharminox 151010.120 Philogen 151410.121 PhiloGene 151810.122 Pierre Fabre 152210.123 Progen 152810.124 Protein Sciences 153210.125 Protgen 153710.126 PTC Therapeutics 154210.127 Receptor BioLogix 154910.128 Regeneron 155310.129 Rexahn 156110.130 Rigel 156510.131 Sanofi 156910.132 Santaris Pharma 157610.133 Scancell 158210.134 SciClone Pharmaceuticals 158610.135 Semafore Pharmaceuticals 159010.136 Shionogi 159610.137 Simcere Pharmaceuticals 160010.138 Spear Therapeutics 160810.139 SRI International 161210.140 Stainwei Biotech 161810.141 SuperGen 162210.142 Switch Pharma 162610.143 SynDevRx 163010.144 Taiho 163410.145 Tau Therapeutics 163810.146 ThromboGenics 164210.147 Tigris Pharmaceuticals 164610.148 ToolGen 165010.149 TopoTarget 165710.150 Tracon Pharmaceuticals 166110.151 UCB 166510.152 VBL Therapeutics 167210.153 Wilex 167610.154 Xerion 168211 Disclaimer 168612 Drug Index 168713 Company Index 1697

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 367Figure 2: The Drug-Target Competitive Landscape of Angiogenesis Affecting Drugs in Oncology - Large Cluster 369Figure 3: The Drug-Target Competitive Landscape Angiogenesis Affecting Drugs in Oncology - Smaller Clusters 370Figure 4: Head-to-Head Targeting Competitive Landscape of Angiogenesis Affecting Drugs in Oncology 371Figure 5: Distribution of Compound Strategies among Angiogenesis Affecting Cancer Drugs 703Figure 6: Primary Sub-cellular Localization of Drug Targets 704Figure 7: Number of Companies per Ranking Level 855

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Angiogenesis Affecting Drug Pipeline in Oncology by Stage of Development 37Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Oncology 37Table 4: Overview of Drug Target Strategy Themes 42Table 5: Terminally Ceased Targets of Angiogenesis Affecting Drugs in Oncology 43Table 6: Official Gene Name to Target Profle 44Table 7: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 356Table 8: Identity of Drug Targets with Available Biological Structures 360Table 9: Number of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 365Table 10: Available Protein Expression Profiles of Angiogenesis Affecting Drug Targets in Oncology 372Table 11: Pathway Summary 377Table 12: Drug Targets without any Identified Assigned Pathways 377Table 13: Pathway Profiles According to BioCarta of Angiogenesis Affecting Drug Targets in Oncology 379Table 14: Pathway Profiles According to KEGG of Angiogenesis Affecting Drug Targets in Oncology 397Table 15: Pathway Profiles According to NetPath of Angiogenesis Affecting Drug Targets in Oncology 417Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 424Table 17: Top Competitive Target Strategies of Angiogenesis Affecting Drugs in Oncology 425Table 18: New and Unique Target Strategies of Pre-registration and Marketed Angiogenesis Affecting Drugs in Oncology 426Table 19: The Competition Through Close Mechanistic Approximation Between Angiogenesis Affecting Drugs in Oncology in Pre-registration to Marketed 427Table 20: New and Unique Target Strategies in Phase III Clinical Development of Angiogenesis Affecting Drugs in Oncology 428Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Angiogenesis Affecting Drugs in Oncology 430Table 22: New and Unique Target Strategies in Phase II Clinical Development of Angiogenesis Affecting Drugs in Oncology 431Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Angiogenesis Affecting Drugs in Oncology 435Table 24: New and Unique Target Strategies in Phase I Clinical Development of Angiogenesis Affecting Drugs in Oncology 438Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Angiogenesis Affecting Drugs in Oncology 442Table 26: New and Unique Target Strategies in Preclinical Development of Angiogenesis Affecting Drugs in Oncology 446Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Angiogenesis Affecting Drugs in Oncology 449Table 28: Target Strategies of No Data, Suspended and Terminated Angiogenesis Affecting Drugs in Oncology 450Table 29: Connecting Target Strategy with Its Profile Identification Number 454Table 30: The Competition Through Close Mechanistic Approximation Among Angiogenesis Affecting Drugs in Oncology 660Table 31: Overview of Compound Strategy Competition Among Angiogenesis Affecting Cancer Drugs 668Table 32: Overview of the Competitive Landscape of Small Molecule Based Angiogenesis Affecting Cancer Drugs 670Table 33: Competitive Comparison of Target Strategies of Small Molecule Angiogenesis Affecting Cancer Drugs 671Table 34: Pursued Target Strategies of Small Molecule Drugs Based Angiogenesis Affecting Cancer Drugs 675Table 35: Overview of the Competitive Landscape of Peptide Based Angiogenesis Affecting Cancer Drugs 683Table 36: Competitive Comparison of Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684Table 37: Pursued Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684Table 38: Overview of the Competitive Landscape of Protein Based Angiogenesis Affecting Cancer Drugs 686Table 39: Competitive Comparison of Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687Table 40: Pursued Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687Table 41: Overview of the Competitive Landscape of Antibody Based Angiogenesis Affecting Cancer Drugs 689Table 42: Competitive Comparison of Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 690Table 43: Pursued Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 691Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 695Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696Table 46: Pursued Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696Table 47: Vectors in Gene Therapy 697Table 48: Overview of the Competitive Landscape of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 697Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 698Table 50: Pursued Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 699Table 51:Overview of the Competitive Landscape of Reformulated Angiogenesis Affecting Cancer Drugs 700Table 52: Competitive Comparison of Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 701Table 53: Pursued Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 702Table 54: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Cancer Drug Targets 704Table 55 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs 711Table 56: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia 713Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia 714Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 715Table 59: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer 717Table 60: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 717Table 61: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma 718Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer 719Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer 720Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer 721Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 722Table 66: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer 724Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer 725Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 727Table 69: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer 728Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 730Table 71: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general) 734Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid 735Table 73: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 736Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer 737Table 75: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemopreventative 738Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia 739Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia 740Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelomonocytic Leukemia 741Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer 741Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer 742Table 81: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 745Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer 748Table 83: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 749Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer 750Table 85: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 751Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma 752Table 87: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general) 753Table 88: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 755Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer 756Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 757Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer 759Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 760Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer 761Table 94: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 763Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hematological Cancer (general) 764Table 96: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma 765Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma 766Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma 767Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general) 768Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma 769Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer 770Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 772Table 103: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general) 774Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphangioleiomyomatosis 776Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general) 777Table 106: The Competition through Close Mechanistic Approximation between Lymphoma Drugs 778Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia 779Table 108: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mastocytosis 779Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma 780Table 110: The Competition through Close Mechanistic Approximation between Melanoma Drugs 782Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma 784Table 112: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 786Table 113: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome 787Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma 789Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs 790Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer 792Table 117: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general) 793Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 794Table 119: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 794Table 120: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neurofibromatosis 796Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma 797Table 122: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 798Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer 799Table 124: The Competition through Close Mechanistic Approximation between non-Small Cell Lung Cancer Drugs 802Table 125: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer 805Table 126: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 806Table 127: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer 807Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma 808Table 129: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer 809Table 130: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 811Table 131: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer 813Table 132: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 815Table 133: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer 816Table 134: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 817Table 135: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer 818Table 136: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 820Table 137: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 822Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Infection 822Table 139: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer 823Table 140: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 826Table 141: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general) 828Table 142: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 829Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer 830Table 144: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 831Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma 833Table 146: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 834Table 147: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor 835Table 148: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 837Table 149: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer 839Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma 840Table 151: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma 841Table 152: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer 842Table 153: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer 843Table 154: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified 845Table 155: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct 848Table 156: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia 848Table 157: Competitive Summary by Investigator of Angiogenesis Affecting Drug Development 849Table 158: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology 853Table 159: Example of a Competitive Fall-Out Table (Targeting KDR/Modified) 861Table 160: Abbott's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 867Table 161: Acceleron Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 876Table 162: Access'Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 880Table 163: Active Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 884Table 164: Adherex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 889Table 165: Advantagene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 896Table 166: Advaxis'Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 902Table 167: Advenchen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 906Table 168: Aeterna Zentaris'Include

To order this report:Pathology Industry: Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
2. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
3. KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
4. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
5. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
6. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
7. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
8. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
9. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... -- Site Profile: --> ... Speech Recognition People, announced their latest primary healthcare case study where ... turnaround times and to save the practice money. Site ... Challenge: --> ,- Wirral CCG ,- VoicePower ... doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and ... their Napa Valley office. The technique utilizes the body’s own healing abilities to ... Dr. Furnas, are part of only a select few cosmetic surgeons bringing this ...
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s leading ... Big Game. Take the stress out of your party preparation – follow these easy, ... every stage of the game. , “The key to hosting a successful game-day party ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, Dr. ... Cheng, CitiDent offers a complete range of oral health care, including general dentistry, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... for Patients with Rare Diseases, a continuing medical education (CME) event presented by ... first of its kind—and a first for ACCORD, whose mission is to provide ...
Breaking Medicine News(10 mins):